DeCoster M A, Klette K L, Knight E S, Tortella F C
Walter Reed Army Institute of Research, Department of Medical Neurosciences, Washington, DC 20307-5100, USA.
Brain Res. 1995 Feb 6;671(1):45-53. doi: 10.1016/0006-8993(94)01294-r.
The role of the putative sigma receptor in mediating neuroprotection against glutamate-induced neuronal injury was examined in mature cultured rat cortical neurons. With the exception of the selective sigma 1 ligand (+)-3-PPP, all of the sigma ligands tested were neuroprotective, preventing glutamate-induced morphological changes and increases in LDH release. Their rank order of neuroprotective potency (and EC50 values) was as follows: (+)-SKF 10,047 (0.81 microM) > (+)- cyclazocine (2.3 microM) > dextromethorphan (3.1 microM) = haloperidol (3.7 microM) > (+)-pentazocine (8.5 microM) > DTG (42.7 microM) = carbetapentane (46.3 microM). When corrected for relative sigma versus PCP binding affinity, it appears that a positive correlation exists between neuroprotective potency and sigma 1 site affinity. However, there does not appear to be a significant correlation between neuroprotective potency and the sigma 2 site. Critically, none of the sigma ligands were neurotoxic when tested alone at concentrations at least 5-30 times their respective neuroprotective EC50 values. Results from preliminary experiments with the selective sigma 1 ligand (+)-pentazocine indicated that sigma-mediated neuroprotection may involve the buffering of glutamate-induced calcium flux. Collectively, the results of these in vitro experiments demonstrate that sigma ligands are neuroprotective and therefore deserve further exploration as potential therapeutic agents in in vivo models of CNS injury and neurodegenerative disorders.
在成熟的大鼠皮质神经元培养物中研究了假定的σ受体在介导针对谷氨酸诱导的神经元损伤的神经保护作用中的角色。除了选择性σ1配体(+)-3-PPP外,所有测试的σ配体均具有神经保护作用,可防止谷氨酸诱导的形态变化和乳酸脱氢酶释放增加。它们的神经保护效力(和EC50值)的排序如下:(+)-SKF 10,047(0.81微摩尔)>(+)-环唑辛(2.3微摩尔)>右美沙芬(3.1微摩尔)=氟哌啶醇(3.7微摩尔)>(+)-喷他佐辛(8.5微摩尔)>DTG(42.7微摩尔)=卡比戊烷(46.3微摩尔)。当校正相对σ与PCP结合亲和力时,神经保护效力与σ1位点亲和力之间似乎存在正相关。然而,神经保护效力与σ2位点之间似乎没有显著相关性。至关重要的是,当单独以至少为其各自神经保护EC50值5至30倍的浓度进行测试时,没有一种σ配体具有神经毒性。使用选择性σ1配体(+)-喷他佐辛的初步实验结果表明,σ介导的神经保护作用可能涉及对谷氨酸诱导钙通量的缓冲。总体而言,这些体外实验的结果表明,σ配体具有神经保护作用,因此作为中枢神经系统损伤和神经退行性疾病体内模型中的潜在治疗药物值得进一步探索。